is our passion

Ludwig Institute for Cancer Research, Gilman Drive, La Jolla, CA, USA

Home / Ludwig Cancer Research

Ludwig Cancer Research

Ludwig Cancer Research is an international community of distinguished scientists dedicated to preventing and controlling cancer. American businessman Daniel K. Ludwig began to support cancer research with the establishment of the Ludwig Institute for Cancer Research in 1971. Today, the scientific efforts endowed through his resources have grown to encompass the Ludwig Institute and the Ludwig Centers at six U.S. institutions, all pursuing breakthroughs to alter the course of cancer.

The Ludwig Institute for Cancer Research Ltd is an international not-for-profit organization with a more than 45-year legacy of pioneering cancer discoveries. The Institute provides its scientists from around the world with the resources and the flexibility to realize the life-changing potential of their work and see their discoveries advance human health. This philosophy, combined with robust translational programs, maximizes the potential of breakthrough discoveries to be more attractive for commercial development.

The Ludwig Institute conducts its own research and clinical trials, making it a bridge from the most basic questions of life to the most pressing needs of cancer care. Since its inception, the Institute has invested more than $1.8 billion of its own resources in cancer research, and has an endowment valued at $1.3 billion. The Institute’s assets are managed by the LICR Fund.

April 8, 2021
NOMIS Awardee Don Cleveland and colleagues have identified how phase separation of the RNA-binding protein TDP-43 can be regulated through RNA binding, disease-causing mutation, posttranslational modification, or chaperone activity inside […]
June 25, 2020
In a major breakthrough, NOMIS Awardee Don W. Cleveland and colleagues have identified a potentially powerful and chemically feasible approach to treating Parkinson’s disease by replacing lost neurons. Their findings […]
November 19, 2018
The groundbreaking research of NOMIS Distinguished Scientist Awardee Don W. Cleveland is the subject of Swiss newspaper the Tages Anzeiger’s article “Der Bändiger von schweren Hirnleiden” (“The tamer of severe […]
October 5, 2018
In recognition of their outstanding contributions to the advancement of science and human progress through pioneering, collaborative and innovative research, the 2018 NOMIS Distinguished Scientist and Scholar Award was presented to […]
December 1, 2022
Abstract: The multifunctional nucleocapsid (N) protein in SARS-CoV-2 binds the ~30 kb viral RNA genome to aid its packaging into the 80–90 nm membrane-enveloped virion. The N protein is composed of […]
January 1, 2022
Abstract: While acetylated, RNA-binding-deficient TDP-43 reversibly phase separates within nuclei into complex droplets (anisosomes) comprised of TDP-43-containing liquid outer shells and liquid centres of HSP70-family chaperones, cytoplasmic aggregates of TDP-43 are […]
August 1, 2021
Abstract: Methods to enhance adult neurogenesis by reprogramming glial cells into neurons enable production of new neurons in the adult nervous system. Development of therapeutically viable approaches to induce new neurons […]
February 5, 2021
Abstract: The RNA binding protein TDP-43 forms intranuclear or cytoplasmic aggregates in age-related neurodegenerative diseases. In this study, we found that RNA binding-deficient TDP-43 (produced by neurodegeneration-causing mutations or posttranslational acetylation […]
June 25, 2020
Abstract: Parkinson’s disease is characterized by loss of dopamine neurons in the substantia nigra1. Similar to other major neurodegenerative disorders, there are no disease-modifying treatments for Parkinson’s disease. While most treatment […]
April 17, 2019
Abstract: TDP-43 aggregation is the major hallmark of multiple neurodegenerative diseases, including ALS and FTD. Gasset-Rosa et al. demonstrate that transient stress induces long-lasting cytoplasmic TDP-43 de-mixing independent of stress granules, […]